Major Depressive Disorder Clinical Trials in San Diego, California

9 studies are recruiting for major depressive disorder in San Diego, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

   This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, San Diego, California

   Locations

   19 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07105111 on ClinicalTrials.gov

2. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

   X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Artemis Institute for Clinical Research, San Diego, California

   Locations

   50 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT07076407 on ClinicalTrials.gov

3. Enhancing Veteran-Clinical Collaboration in VA PRRCs

   Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives. Although traditional treatments tend to focus on symptom remission, Veterans prioritize a range of treatment goals, including…

   Stage

   Not phased

   Ages

   18 and older

   Site

   VA San Diego Healthcare System, San Diego, CA, San Diego, California

   Locations

   3 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT06898879 on ClinicalTrials.gov

4. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

   A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Kadima Neuropsychiatry Institute, San Diego, California

   Locations

   30 in total

   Run by

   Definium Therapeutics US, Inc.

   See if you can join NCT07592689 on ClinicalTrials.gov

5. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, San Diego, California

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

6. Mindfulness Engaged Neurostimulation for Depression (MEND II)

   Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of ~30%. Additionally, r…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   UC San Diego Health Psychiatry, San Diego, California

   Run by

   University of California, San Diego

   See if you can join NCT07512284 on ClinicalTrials.gov

7. Maintenance rTMS for Depression (Maitr-De)

   Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   University of California, San Diego, San Diego, California

   Locations

   3 in total

   Run by

   University of California, San Diego

   See if you can join NCT06938841 on ClinicalTrials.gov

8. Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, San Diego, California

   Locations

   18 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06786624 on ClinicalTrials.gov

9. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

   This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Clinical Research Site, San Diego, California

   Locations

   40 in total

   Run by

   Axsome Therapeutics, Inc.

   See if you can join NCT06223880 on ClinicalTrials.gov